share_log

Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $148 Price Target

Benzinga ·  Dec 16, 2024 21:25  · Ratings

Wedbush analyst Laura Chico reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and maintains $148 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment